Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Recent Nano-based Therapeutic Intervention of Bioactive Sesquiterpenes: Prospects in Cancer Therapeutics

Author(s): Mohammad A. Ansari*, Khan F. Badrealam, Asrar Alam, Saba Tufail, Gulshan Khalique, Mohammad J. Equbal*, Mohammad A. Alzohairy, Ahmad Almatroudi, Mohammad N. Alomary and Faheem H. Pottoo

Volume 26, Issue 11, 2020

Page: [1138 - 1144] Pages: 7

DOI: 10.2174/1381612826666200116151522

Price: $65

Abstract

In the recent scenario, nanotechnology-based therapeutics intervention has gained tremendous impetus all across the globe. Nano-based pharmacological intervention of various bioactive compounds has been explored on an increasing scale. Sesquiterpenes are major constituents of essential oils (EOs) present in various plant species which possess intriguing therapeutic potentials. However, owing to their poor physicochemical properties; they have pharmacological limitations. Recent advances in nano-based therapeutic interventions offer various avenues to improve their therapeutic applicability. Reckoning with these, the present review collates various nano-based therapeutic intervention of sesquiterpenes with prospective potential against various debilitating diseases especially cancer. In our viewpoint, considering the burgeoning advancement in the field of nanomedicine; in the near future, the clinical applicability of these nano-formulated sesquiterpenes can be foreseen with great enthusiasm.

Keywords: Sesquiterpenes, nanoformulations, cancer, therapeutics, Nano-based pharmacological intervention, essential oils.

« Previous Next »
[1]
Ren Y, Yu J, Kinghorn AD. Development of anticancer agents from plant-derived sesquiterpene lactones. Curr Med Chem 2016; 23(23): 2397-420.
[http://dx.doi.org/10.2174/0929867323666160510123255] [PMID: 27160533]
[2]
Andersen TB, Rasmussen SA, Christensen SB, Simonsen HT. Biosynthesis of tovarol and other sesquiterpenoids in Thapsia laciniata Rouy. Phytochemistry 2019; 157: 168-74.
[http://dx.doi.org/10.1016/j.phytochem.2018.10.027] [PMID: 30412824]
[3]
Brown GD. The biosynthesis of artemisinin (Qinghaosu) and the phytochemistry of Artemisia annua L. (Qinghao). Molecules 2010; 15(11): 7603-98.
[http://dx.doi.org/10.3390/molecules15117603] [PMID: 21030913]
[4]
Bains S, Thakur V, Kaur J, Singh K, Kaur R. Elucidating genes involved in sesquiterpenoid and flavonoid biosynthetic pathways in Saussurea lappa by de novo leaf transcriptome analysis. Genomics 2019; 111(6): 1474-82.
[PMID: 30343181]
[5]
Frey M, Schmauder K, Pateraki I, Spring O. Biosynthesis of eupatolide-a metabolic route for sesquiterpene lactone formation involving the p450 enzyme CYP71DD6. ACS Chem Biol 2018; 13(6): 1536-43.
[http://dx.doi.org/10.1021/acschembio.8b00126] [PMID: 29758164]
[6]
Liffert R, Linden A, Gademann K. Total synthesis of the sesquiterpenoid periconianone a based on a postulated biogenesis. J Am Chem Soc 2017; 139(45): 16096-9.
[http://dx.doi.org/10.1021/jacs.7b10053] [PMID: 29076340]
[7]
Merfort I. Perspectives on sesquiterpene lactones in inflammation and cancer. Curr Drug Targets 2011; 12(11): 1560-73.
[http://dx.doi.org/10.2174/138945011798109437] [PMID: 21561425]
[8]
Chadwick M, Trewin H, Gawthrop F, Wagstaff C. Sesquiterpenoids lactones: benefits to plants and people. Int J Mol Sci 2013; 14(6): 12780-805.
[http://dx.doi.org/10.3390/ijms140612780] [PMID: 23783276]
[9]
Ghantous A, Gali-Muhtasib H, Vuorela H, Saliba NA, Darwiche N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov Today 2010; 15(15-16): 668-78.
[http://dx.doi.org/10.1016/j.drudis.2010.06.002] [PMID: 20541036]
[10]
Branquinho RT, Mosqueira VC, de Oliveira-Silva JC, Simões-Silva MR, Saúde-Guimarães DA, de Lana M. Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease. Antimicrob Agents Chemother 2014; 58(4): 2067-75.
[http://dx.doi.org/10.1128/AAC.00617-13] [PMID: 24449777]
[11]
Khan BF, Hamidullah , Dwivedi S, Konwar R, Zubair S, Owais M. Potential of bacterial culture media in biofabrication of metal nanoparticles and the therapeutic potential of the as-synthesized nanoparticles in conjunction with artemisinin against MDA-MB-231 breast cancer cells. J Cell Physiol 2019; 234(5): 6951-64.
[12]
Want MY, Islammudin M, Chouhan G, et al. Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis. Int J Nanomedicine 2017; 12: 2189-204.
[http://dx.doi.org/10.2147/IJN.S106548] [PMID: 28356736]
[13]
Baldissera MD, Souza CF, Grando TH, et al. Nerolidol-loaded nanospheres prevent behavioral impairment via ameliorating Na+, K+-ATPase and AChE activities as well as reducing oxidative stress in the brain of Trypanosoma evansi-infected mice. Naunyn Schmiedebergs Arch Pharmacol 2017; 390(2): 139-48.
[http://dx.doi.org/10.1007/s00210-016-1313-8] [PMID: 27807596]
[14]
Baldissera MD, Grando TH, Souza CF, et al. Nerolidol nanospheres increases its trypanocidal efficacy against Trypanosoma evansi: New approach against diminazene aceturate resistance and toxicity. Exp Parasitol 2016; 166: 144-9.
[http://dx.doi.org/10.1016/j.exppara.2016.04.015] [PMID: 27109312]
[15]
Badrealam KF, Owais M. Nano-Sized Drug Delivery Systems: development and implication in treatment of hepatocellular carcinoma. Dig Dis 2015; 33(5): 675-82.
[http://dx.doi.org/10.1159/000438497] [PMID: 26398762]
[16]
Banerjee R. Nanotechnology in drug delivery: present status and a glimpse into the future. Ther Deliv 2018; 9(4): 231-2.
[http://dx.doi.org/10.4155/tde-2018-0014] [PMID: 29540128]
[17]
Kantamneni H, Zevon M, Donzanti MJ, et al. Surveillance nanotechnology for multi-organ cancer metastases. Nat Biomed Eng 2017; 1: 993-1003.
[http://dx.doi.org/10.1038/s41551-017-0167-9] [PMID: 29531851]
[18]
Tonigold M, Simon J, Estupiñán D, et al. Pre-adsorption of antibodies enables targeting of nanocarriers despite a biomolecular corona. Nat Nanotechnol 2018; 13(9): 862-9.
[http://dx.doi.org/10.1038/s41565-018-0171-6] [PMID: 29915272]
[19]
De Matteis V. Exposure to inorganic nanoparticles: routes of entry, immune response, biodistribution and in vitro/in vivo toxicity evaluation. Toxics 2017; 5(4): 5.
[http://dx.doi.org/10.3390/toxics5040029] [PMID: 29051461]
[20]
Jahan ST, Sadat SMA, Walliser M, Haddadi A. Targeted therapeutic nanoparticles: an immense promise to fight against cancer. J Drug Deliv 2017; 20179090325
[http://dx.doi.org/10.1155/2017/9090325] [PMID: 29464123]
[21]
Pareek A, Suthar M, Rathore GS, Bansal V. Feverfew (Tanacetum parthenium L.): A systematic review. Pharmacogn Rev 2011; 5(9): 103-10.
[http://dx.doi.org/10.4103/0973-7847.79105] [PMID: 22096324]
[22]
Karmakar A, Xu Y, Mustafa T, et al. Nanodelivery of parthenolide using functionalized nanographene enhances its anticancer activity. RSC Advances 2015; 5(4): 2411-20.
[http://dx.doi.org/10.1039/C4RA10871J] [PMID: 25574376]
[23]
Zong H, Sen S, Zhang G, et al. In vivo targeting of leukemia stem cells by directing parthenolide-loaded nanoparticles to the bone marrow niche. Leukemia 2016; 30(7): 1582-6.
[http://dx.doi.org/10.1038/leu.2015.343] [PMID: 26669973]
[24]
Hassane DC, Sen S, Minhajuddin M, et al. Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways. Blood 2010; 116(26): 5983-90.
[http://dx.doi.org/10.1182/blood-2010-04-278044] [PMID: 20889920]
[25]
Kumari P, Ghosh B, Biswas S. Nanocarriers for cancer-targeted drug delivery. J Drug Target 2016; 24(3): 179-91.
[http://dx.doi.org/10.3109/1061186X.2015.1051049] [PMID: 26061298]
[26]
Jin X, Zhou J, Zhang Z, Lv H. The combined administration of parthenolide and ginsenoside CK in long circulation liposomes with targeted tLyp-1 ligand induce mitochondria-mediated lung cancer apoptosis. Artif Cells Nanomed Biotechnol 2018; 46(Suppl. 3): S931-42.
[http://dx.doi.org/10.1080/21691401.2018.1518913] [PMID: 30307334]
[27]
Aderibigbe BA. Design of drug delivery systems containing artemisinin and its derivatives. Molecules 2017; 22(2): 22.
[http://dx.doi.org/10.3390/molecules22020323] [PMID: 28230749]
[28]
Medhi B, Patyar S, Rao RS, Byrav D S P, Prakash A. Pharmacokinetic and toxicological profile of artemisinin compounds: an update. Pharmacology 2009; 84(6): 323-32.
[http://dx.doi.org/10.1159/000252658] [PMID: 19851082]
[29]
Zhang H, Hou L, Jiao X, Ji Y, Zhu X, Zhang Z. Transferrin-mediated fullerenes nanoparticles as Fe(2+)-dependent drug vehicles for synergistic anti-tumor efficacy. Biomaterials 2015; 37: 353-66.
[http://dx.doi.org/10.1016/j.biomaterials.2014.10.031] [PMID: 25453964]
[30]
Zhang H, Ji Y, Chen Q, et al. Enhancement of cytotoxicity of artemisinin toward cancer cells by transferrin-mediated carbon nanotubes nanoparticles. J Drug Target 2015; 23(6): 552-67.
[http://dx.doi.org/10.3109/1061186X.2015.1016437] [PMID: 25754587]
[31]
Isacchi B, Arrigucci S, la Marca G, et al. Conventional and long-circulating liposomes of artemisinin: preparation, characterization, and pharmacokinetic profile in mice. J Liposome Res 2011; 21(3): 237-44.
[http://dx.doi.org/10.3109/08982104.2010.539185] [PMID: 21158702]
[32]
Gharib A, Faezizadeh Z, Mesbah-Namin SA, Saravani R. Preparation, characterization and in vitro efficacy of magnetic nanoliposomes containing the artemisinin and transferrin. Daru 2014; 22: 44.
[http://dx.doi.org/10.1186/2008-2231-22-44] [PMID: 24887240]
[33]
Li XY, Zhao Y, Sun MG, et al. Multifunctional liposomes loaded with paclitaxel and artemether for treatment of invasive brain glioma. Biomaterials 2014; 35(21): 5591-604.
[http://dx.doi.org/10.1016/j.biomaterials.2014.03.049] [PMID: 24726749]
[34]
Isacchi B, Bergonzi MC, Grazioso M, et al. Artemisinin and artemisinin plus curcumin liposomal formulations: enhanced antimalarial efficacy against Plasmodium berghei-infected mice. Eur J Pharm Biopharm 2012; 80(3): 528-34.
[http://dx.doi.org/10.1016/j.ejpb.2011.11.015] [PMID: 22142592]
[35]
Dai L, Wang L, Deng L, et al. Novel multiarm polyethylene glycol-dihydroartemisinin conjugates enhancing therapeutic efficacy in non-small-cell lung cancer. Sci Rep 2014; 4: 5871.
[http://dx.doi.org/10.1038/srep05871] [PMID: 25070490]
[36]
Ismail M, Du Y, Ling L, Li X. Artesunate-heparin conjugate based nanocapsules with improved pharmacokinetics to combat malaria. Int J Pharm 2019; 562: 162-71.
[http://dx.doi.org/10.1016/j.ijpharm.2019.03.031] [PMID: 30902709]
[37]
Zhang X, Qiao H, Liu J, et al. Dihydroartemisinin loaded nanostructured lipid carriers (DHA-NLC): evaluation of pharmacokinetics and tissue distribution after intravenous administration to rats. Pharmazie 2010; 65(9): 670-8.
[PMID: 21038844]
[38]
Tran TH, Nguyen TD, Poudel BK, et al. Development and evaluation of artesunate-loaded chitosan-coated lipid nanocapsule as a potential drug delivery system against breast cancer. AAPS PharmSciTech 2015; 16(6): 1307-16.
[http://dx.doi.org/10.1208/s12249-015-0311-3] [PMID: 25787869]
[39]
Marques AM, Barreto AL, Batista EM, et al. Chemistry and biological activity of essential oils from Piper claussenianum (Piperaceae). Nat Prod Commun 2010; 5(11): 1837-40.
[http://dx.doi.org/10.1177/1934578X1000501131] [PMID: 21213995]
[40]
Lapczynski A, Bhatia SP, Letizia CS, Api AM. Fragrance material review on nerolidol (isomer unspecified). Food Chem Toxicol 2008; 46(Suppl. 11): S247-50.
[http://dx.doi.org/10.1016/j.fct.2008.06.063] [PMID: 18640205]
[41]
Park MJ, Gwak KS, Yang I, et al. Effect of citral, eugenol, nerolidol and alpha-terpineol on the ultrastructural changes of Trichophyton mentagrophytes. Fitoterapia 2009; 80(5): 290-6.
[http://dx.doi.org/10.1016/j.fitote.2009.03.007] [PMID: 19345255]
[42]
Branquinho RT, Roy J, Farah C, et al. Biodegradable polymeric nanocapsules prevent cardiotoxicity of anti-trypanosomal lychnopholide. Sci Rep 2017; 7: 44998.
[http://dx.doi.org/10.1038/srep44998] [PMID: 28349937]
[43]
Di Sotto A, Paolicelli P, Nardoni M, et al. SPC Liposomes as possible delivery systems for improving bioavailability of the natural sesquiterpene β-caryophyllene: lamellarity and drug-loading as key features for a rational drug delivery design. Pharmaceutics 2018; 10(4): 10.
[http://dx.doi.org/10.3390/pharmaceutics10040274] [PMID: 30551617]
[44]
Yu J, Xueting W, Ying L, Xue H, Xiaotong L, Xinying H. Synthesis of nerolidol functionalized gold nanoparticles for wound regeneration in people with diabetic foot ulcers in nursing care management. Sci Adv Mater 2018; 10: 1775-81.
[http://dx.doi.org/10.1166/sam.2018.3389]
[45]
Barkat MA, Harshita , Ahmad I, et al. Nanosuspension-based aloe vera gel of silver sulfadiazine with improved wound healing activity. AAPS PharmSciTech 2017; 18(8): 3274-85.
[http://dx.doi.org/10.1208/s12249-017-0817-y] [PMID: 28584900]

Rights & Permissions Print Cite
Article Metrics
9
© 2024 Bentham Science Publishers | Privacy Policy